Alza/Baxter I.V. drug delivery system
Executive Summary
Baxter recently filed first ANDA for new in-line I.V. drug delivery system developed under licensing arrangement with Alza, and is "in process" of preparing ANDAs for other initial drugs to be used in the system, firms announced Dec. 4. The new system self-reconstitutes powder or liquid form drugs and can be used with standard I.V. drug delivery equipment, firms said, making the system applicable to most drugs currently given I.V. Baxter is understood to be considering replacing Mini-bag I.V. with Alza technology.
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: